Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
et al., The Lancent Regional Health, doi:10.1016/j.lanwpc.2023.100694
, Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized.., The Lancent Regional Health, doi:10.1016/j.lanwpc.2023.100694
RCT 264 patients in China, showing no significant difference in outcomes with paxlovid.
|
risk of death, 37.5% lower, RR 0.62, p = 0.57, treatment 5 of 132 (3.8%), control 8 of 132 (6.1%), NNT 44, day 28.
|
|
risk of mechanical ventilation, 66.7% higher, RR 1.67, p = 0.44, treatment 10 of 132 (7.6%), control 6 of 132 (4.5%).
|
|
ICU time, 9.5% higher, relative time 1.10, p = 0.80, treatment 132, control 132.
|
|
risk of progression, 26.7% higher, RR 1.27, p = 0.58, treatment 19 of 132 (14.4%), control 15 of 132 (11.4%), acute exacerbation of chronic disease.
|
|
time to viral-, 4.8% lower, relative time 0.95, p = 0.42, treatment 132, control 132.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Liu et al., 5 Feb 2023, Randomized Controlled Trial, China, peer-reviewed, 34 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.